Oliver Bechter

11.3k total citations
95 papers, 1.7k citations indexed

About

Oliver Bechter is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Oliver Bechter has authored 95 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 36 papers in Molecular Biology and 18 papers in Immunology. Recurrent topics in Oliver Bechter's work include Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (12 papers). Oliver Bechter is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (12 papers). Oliver Bechter collaborates with scholars based in Belgium, United States and Italy. Oliver Bechter's co-authors include Jerry W. Shay, Woodring E. Wright, Patrick Schöffski, Ying Zou, Josef Thaler, Thomas Kühr, Wolfgang Hilbe, William H. Walker, Wolfgang Eisterer and Georg Pall and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Oliver Bechter

91 papers receiving 1.7k citations

Peers

Countries citing papers authored by Oliver Bechter

Since Specialization

Citations

This map shows the geographic impact of Oliver Bechter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Bechter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Bechter more than expected).

Fields of papers citing papers by Oliver Bechter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Bechter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Bechter. The network helps show where Oliver Bechter may publish in the future.

Co-authorship network of co-authors of Oliver Bechter

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Bechter. A scholar is included among the top collaborators of Oliver Bechter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Bechter. Oliver Bechter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumor immunity 2025 ·The Journal of Experimental Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Roberto Vendramin, Alessandro Cuomo, Joanna Poźniak, (unknown), Marcella Baldewijns, Sébastien P. Tabruyn, Oliver Bechter, Maria Francesca Baietti, Elisabetta Groaz, Tiziana Bonaldi, Eleonora Leucci	0
2	Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation 2025 ·Cancer Discovery ·Rosa Trotta, (unknown), (unknown), (unknown), (unknown), (unknown), Joanna Poźniak, Jonas Dehairs, Lotte Vanheer, (unknown), Veerle Boecxstaens, Oliver Bechter, Francesca M. Bosisio, Johannes V. Swinnen, Jean‐Christophe Marine, Massimiliano Mazzone	5
3	Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A128 Polymorphism 2024 ·Clinical Genitourinary Cancer* ·(unknown), Peter H. Nissen, Frede Donskov, Agnieszka Woźniak, Yannick Van Herck, (unknown), (unknown), Diether Lambrechts, Oliver Bechter, Marcella Baldewijns, Eduard Roussel, Annouschka Laenen, Benoit Beuselinck	1
4	Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses 2024 ·Clinical Cancer Research ·Anna Morena D’Alise, Guido Leoni, Gabriella Cotugno, (unknown), Rosa Vitale, Valentino Ruzza, (unknown), Laura Antonucci, Elisa Micarelli, (unknown), Sven Gogov, Alessia Capone, Sarah Runswick, Juan Martín-Liberal, Emiliano Calvo, Víctor Moreno, Stefan N. Symeonides, Elisa Scarselli, Oliver Bechter	23
5	Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial 2024 ·Future Oncology ·Alexander J. Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D. Lewis, Ketty Peris, Oliver Bechter, James Harnett, Vera Mastey, Matthew Reaney, Christina Daskalopoulou, (unknown), (unknown), (unknown), Suk-Young Yoo, Kosalai Kal Mohan, (unknown), Timothy G. Bowler, Matthew G. Fury, Aleksander Sekulic	0
6	Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study 2023 ·Acta Oncologica ·(unknown), Feng Jung Sherida H. Woei-A-Jin, Rita Van Ginderdeuren, Christophe M. Deroose, Annouschka Laenen, Guy S. Missotten, Dietmar Rudolf Thal, Oliver Bechter, Patrick Schöffski, Paul M. Clément	2
7	Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response 2022 ·Cancer Research ·Asier Antoranz, Yannick Van Herck, Maddalena M. Bolognesi, (unknown), Arman Rahman, William M. Gallagher, Veerle Boecxstaens, Jean‐Christophe Marine, Giorgio Cattoretti, Joost J. van den Oord, Frederik De Smet, Oliver Bechter, Francesca M. Bosisio	22
8	Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer 2021 ·Cancer Immunology Research ·(unknown), Ana I. Oliveira, (unknown), Heleen H. Van Acker, Ewout Landeloos, Jens Serneels, (unknown), Yannick Van Herck, (unknown), (unknown), Abhishek D. Garg, Véronique Flamand, Luca Tamagnone, Jean‐Christophe Marine, Mario Di Matteo, Bruno M. Costa, Oliver Bechter, Massimiliano Mazzone	11
9	Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma 2021 ·The Journal of Experimental Medicine ·Roberto Vendramin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Panagiotis Karras, (unknown), Francesca M. Bosisio, (unknown), Jan Rozman, Ivan Gladwyn‐Ng, Lara Rizzotto, Erik Dassi, Stefania Millevoi, Oliver Bechter, Jean‐Christophe Marine, Eleonora Leucci	28
10	Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors 2021 ·Current Oncology ·Lisa Kinget, Oliver Bechter, Kevin Punie, Philip R. Debruyne, Hilde Brems, Paul Clement, Eduard Roussel, Yannick Van Herck, Maarten Albersen, Marcella Baldewijns, Patrick Schöffski, Benoit Beuselinck	3
11	Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome 2021 ·Radiology Imaging Cancer ·(unknown), (unknown), Giorgio Maria Agazzi, Frederik De Keyzer, Olivier Gheysens, Oliver Bechter, Pascal Wolter, Daan Dierickx, Ann Janssens, Gregor Verhoef, Raymond Oyen, Michel Koole, Vincent Vandecaveye	2
12	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas 2021 ·International Journal of Molecular Sciences ·(unknown), Asier Antoranz, Anna Szumera‐Ciećkiewicz, Paweł Teterycz, Piotr Rutkowski, Robert V. Rawson, Richard A. Scolyer, John F. Thompson, Julia Newton‐Bishop, Marguerite Stas, Veerle Boecxstaens, Oliver Bechter, Jurgen Vercauteren, Marjan Garmyn, Joost van den Oord, Francesca M. Bosisio	3
13	Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma 2020 ·European Journal of Clinical Pharmacology ·(unknown), Benoit Beuselinck, (unknown), (unknown), Oliver Bechter, Maarten Albersen, Eduard Roussel, Marcella Baldewijns, Jan Tack, Isabel Spriet	10
14	Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis 2020 ·Sarcoma ·Patrick Schöffski, (unknown), Daphne Hompes, M. Stas, Friedl Sinnaeve, Paul De Leyn, Willy Coosemans, Dirk Van Raemdonck, Esther Hauben, Raf Sciot, Paul M. Clément, Oliver Bechter, Benoit Beuselinck, Feng Jung Sherida H. Woei-A-Jin, Herlinde Dumez, Philippe Nafteux, (unknown)	23
15	1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone 2020 ·Annals of Oncology ·Caroline Robert, Georgina V. Long, James Larkin, Jedd D. Wolchok, Jessica C. Hassel, Dirk Schadendorf, F. Stephen Hodi, Célèste Lebbé, Jean‐Jacques Grob, Kenneth F. Grossmann, John Wagstaff, Jason Chesney, Marcus O. Butler, Oliver Bechter, Iván Márquez‐Rodas, Anna C. Pavlick, Sandra Re, Wim van Dijck, Michael A. Postow, Paolo A. Ascierto	7
16	Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumour 2020 ·European Journal of Nuclear Medicine and Molecular Imaging ·Elin Pauwels, Sofie Celen, Mathilde Vandamme, (unknown), Kristof Baete, Oliver Bechter, Marie Bex, Kim Serdons, Koen Van Laere, Guy Bormans, Christophe M. Deroose	19
17	Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab 2017 ·Acta Clinica Belgica ·(unknown), Thomas Van Cann, Patrick Schöffski, Paul Clement, Oliver Bechter, Isabel Spriet, Ruxandra Coropciuc, Constantinus Politis, (unknown), Joseph Schoenaers, Herlinde Dumez, Patrick Berteloot, Patrick Neven, Kristiaan Nackaerts, Feng Jung Sherida H. Woei-A-Jin, Kevin Punie, Hans Wildiers, Benoit Beuselinck	40
18	Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma 2017 ·Sarcoma ·(unknown), Paul M. Clément, Oliver Bechter, Herlinde Dumez, Annelies Verbiest, Raf Sciot, Daphne Hompes, Friedl Sinnaeve, Erik Van Limbergen, Patrick Schöffski	1
19	Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone 2017 ·Annals of Oncology ·Caroline Robert, James Larkin, Paolo A. Ascierto, Georgina V. Long, Jessica C. Hassel, Dirk Schadendorf, F. Stephen Hodi, Célèste Lebbé, Jean‐Jacques Grob, Kenneth F. Grossmann, John Wagstaff, Jason Chesney, David Hogg, Oliver Bechter, Iván Márquez‐Rodas, Anna C. Pavlick, Damian Walker, Rafia Bhore, Michael A. Postow, Jedd D. Wolchok	12
20	Detection and quantitation of genetically marked acute myeloid leukemia by competitive polymerase chain reaction after autologous bone marrow transplantation 1999 ·Experimental Hematology ·Thomas Kühr, Oliver Bechter, Stephan Geley, Wolfgang Eisterer, (unknown), (unknown), Hermann Dietrich, Wolfgang Hilbe, Reinhard Kofler, Josef Thaler	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact